Dual amylin and calcitonin receptor agonists and uses thereof

Patent metadata

Field	Value
Publication number	US-11541123-B2
Application number	US-202117554022-A
Country	US
Kind code	B2
Filing date	Dec 17, 2021
Priority date	Dec 18, 2020
Publication date	Jan 3, 2023
Grant date	Jan 3, 2023

Abstract

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

First claim

We claim:

1. A compound comprising: Acetyl-ASHLSTAVLGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) 2 -(γ-Glu)-CO—(CH 2 ) 18 —CO 2 H)LS-Aib-ELHKLEDYPRTDVGAESP-NH 2 (SEQ ID NO:2), or a pharmaceutically acceptable salt thereof.

2. A method of treating Type 2 diabetes in a patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

3. A method of treating obesity in a patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

4. A method of treating dyslipidemia in a patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

5. A method of treating non-alcoholic steatohepatitis (NASH) in a patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

6. A method of lowering food intake in a patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

7. A method of lowering body weight in a patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

8. A method of lowering blood glucose in a patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

9. A method of lowering triglycerides in a patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

11. A method of treating a condition in a patient in need thereof, selected from the group consisting of: clinical or pre-clinical diabetes, obesity, NASH, and dyslipidemia, comprising administering to the patient an effective amount of the pharmaceutical composition of claim 10 .

12. A method of treating a condition in a patient in need thereof, selected from the group consisting of: clinical or pre-clinical diabetes, obesity, NASH, and dyslipidemia, comprising administering to the patient an effective amount of the pharmaceutical composition of claim 10 in combination with an effective amount of an incretin or incretin analog.

13. A compound consisting of: Acetyl-ASHLSTAVLGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl) 2 -(γ-Glu)-CO—(CH 2 ) 18 —CO 2 H)LS-Aib-ELHKLEDYPRTDVGAESP-NH 2 (SEQ ID NO:2), or a pharmaceutically acceptable salt thereof.

Assignees

• Lilly Co Eli

Inventors

• Coskun Tamer
• Qu Hongchang

Classifications

• A61K38/22

  Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35) · CPC title

• A61K47/542

  Carboxylic acids, e.g. a fatty acid or an amino acid · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K47/545

  Heterocyclic compounds (A61K47/558 takes precedence) · CPC title

• A61P3/10 Primary

  for hyperglycaemia, e.g. antidiabetics · CPC title